Simcere Pharma Releases 2026 Interim Report and Confirms Move to Fully Electronic Investor Communications

Bulletin Express

Sep 24

Simcere Pharmaceutical Group Limited issued a notice on 24 September 2026 confirming that its 2026 Interim Report is now available in both English and Chinese on the company’s website (www.simcere.com) and the HKEXnews platform (www.hkexnews.hk).

The company highlighted that, in line with the Hong Kong Stock Exchange’s paperless listing regime effective since 31 December 2023 and its own Articles of Association, all future corporate communications—including annual and interim reports, meeting notices, circulars and proxy forms—will be disseminated electronically. Printed copies will no longer be sent automatically.

Non-registered shareholders are advised to supply a functional email address to their respective banks, brokers, custodians, nominees or HKSCC Nominees Limited to ensure timely receipt of electronic notifications. In the absence of an email address, investors will need to monitor the company and HKEXnews websites for new publications.

Shareholders who prefer hard-copy documents can request them free of charge by emailing simcere.ecom@computershare.com.hk or writing to the share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

Investor inquiries can be directed to the company hotline at +86 (25) 8556 6666 during business hours, Monday to Friday. The notification is signed by Chairman and Chief Executive Officer Mr. Ren Jinsheng on behalf of Simcere Pharma’s board.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1167002526"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167002526\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167002526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167002526","market":"hk","top_or_hot":-1,"title":"Simcere Pharma Releases 2026 Interim Report and Confirms Move to Fully Electronic Investor Communications","media":"Bulletin Express","content":"<p>Simcere Pharmaceutical Group Limited issued a notice on 24 September 2026 confirming that its 2026 Interim Report is now available in both English and Chinese on the company’s website (www.simcere.com) and the HKEXnews platform (www.hkexnews.hk).</p>\n<p>The company highlighted that, in line with the Hong Kong Stock Exchange’s paperless listing regime effective since 31 December 2023 and its own Articles of Association, all future corporate communications—including annual and interim reports, meeting notices, circulars and proxy forms—will be disseminated electronically. Printed copies will no longer be sent automatically.</p>\n<p>Non-registered shareholders are advised to supply a functional email address to their respective banks, brokers, custodians, nominees or HKSCC Nominees Limited to ensure timely receipt of electronic notifications. In the absence of an email address, investors will need to monitor the company and HKEXnews websites for new publications.</p>\n<p>Shareholders who prefer hard-copy documents can request them free of charge by emailing simcere.ecom@computershare.com.hk or writing to the share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.</p>\n<p>Investor inquiries can be directed to the company hotline at +86 (25) 8556 6666 during business hours, Monday to Friday. The notification is signed by Chairman and Chief Executive Officer Mr. Ren Jinsheng on behalf of Simcere Pharma’s board.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharma Releases 2026 Interim Report and Confirms Move to Fully Electronic Investor Communications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharma Releases 2026 Interim Report and Confirms Move to Fully Electronic Investor Communications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-24 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Simcere Pharmaceutical Group Limited issued a notice on 24 September 2026 confirming that its 2026 Interim Report is now available in both English and Chinese on the company’s website (www.simcere.com) and the HKEXnews platform (www.hkexnews.hk).</p>\n<p>The company highlighted that, in line with the Hong Kong Stock Exchange’s paperless listing regime effective since 31 December 2023 and its own Articles of Association, all future corporate communications—including annual and interim reports, meeting notices, circulars and proxy forms—will be disseminated electronically. Printed copies will no longer be sent automatically.</p>\n<p>Non-registered shareholders are advised to supply a functional email address to their respective banks, brokers, custodians, nominees or HKSCC Nominees Limited to ensure timely receipt of electronic notifications. In the absence of an email address, investors will need to monitor the company and HKEXnews websites for new publications.</p>\n<p>Shareholders who prefer hard-copy documents can request them free of charge by emailing simcere.ecom@computershare.com.hk or writing to the share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.</p>\n<p>Investor inquiries can be directed to the company hotline at +86 (25) 8556 6666 during business hours, Monday to Friday. The notification is signed by Chairman and Chief Executive Officer Mr. Ren Jinsheng on behalf of Simcere Pharma’s board.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1167002526","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167002526","pubTimestamp":1790239657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Simcere Pharmaceutical Group Limited issued a notice on 24 September 2026 confirming that its 2026 Interim Report is now available in both English and Chinese on the company’s website...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声医药发布 2026 年中期报告并确认转向全电子投资者沟通","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical Group Limited issued a notice on 24 September 2026 confirming that its 2026 Interim Report is now available in both English and Chinese on the company’s website (www.simcere.com) and the HKEXnews platform (www.hkexnews.hk).\nThe company highlighted that, in line with the Hong Kong Stock Exchange’s paperless listing regime effective since 31 December 2023 and its own Articles of Association, all future corporate communications—including annual and interim reports, meeting notices, circulars and proxy forms—will be disseminated electronically. Printed copies will no longer be sent automatically.\nNon-registered shareholders are advised to supply a functional email address to their respective banks, brokers, custodians, nominees or HKSCC Nominees Limited to ensure timely receipt of electronic notifications. In the absence of an email address, investors will need to monitor the company and HKEXnews websites for new publications.\nShareholders who prefer hard-copy documents can request them free of charge by emailing simcere.ecom@computershare.com.hk or writing to the share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.\nInvestor inquiries can be directed to the company hotline at +86 (25) 8556 6666 during business hours, Monday to Friday. The notification is signed by Chairman and Chief Executive Officer Mr. Ren Jinsheng on behalf of Simcere Pharma’s board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}